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Abstract
Summary Bone mineral density (BMD) sometimes cannot be
improved by long-term bisphosphonate (BP) therapy in oste-
oporosis (OP). This study showed that lumbar as well as hip
BMD significantly increased after denosumab treatment in
patients not responsive to BPs. Thus, denosumab may be a
strong OP treatment option for BP-unresponsive patients.
Introduction BMD sometimes cannot be improved by long-
term BP therapy.
Methods We administered denosumab to osteoporotic pa-
tients with a poor response to BPs who had been taking them
for 2 years or longer. Ninety-eight women with BP-poor
responsive OP were enrolled in this study. Mean (standard
deviation [SD]) age was 71.2 (6.9) years and mean (SD) du-
ration of BP treatment was 59.9 (34.3) months. We distin-
guished BP responders from non-responders based on chang-
es in BMD values at denosumab commencement (baseline)
from 2 years beforehand.
Results There were no significant differences in age, duration
of BP use, bone turnover markers, or BMD at baseline be-
tween the groups. Prior to denosumab, BMD had increased
significantly in responders and decreased significantly in non-
responders. Bone turnover markers had decreased significant-
ly at 4 months of denosumab treatment (P < 0.001) and lum-
bar and hip BMD were significantly increased at 1 year of
therapy in both groups (P < 0.001). Simple correlation coef-
ficients were −0.337 for lumbar and −0.339 for hip BMD
changes (both P = 0.001) before and after denosumab treat-
ment. Both at the lumbar spine and hips, decreased BMD
before denosumab therapy was significantly associated with
an increase in BMD at 1 year of treatment (spine, t val-
ue = −3.502, P = 0.001, R = 0.113; hip, t value = −3.526,
P = 0.001, R = 0.115).
Conclusions These results suggest that denosumab may be a
strong OP treatment option for BP-unresponsive patients.
Keywords Bisphosphonate . Bisphosphonate-unresponsive .
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Introduction
Osteoporosis (OP) is a widespread skeletal disorder requiring
long-term care and management. The purpose of osteoporotic
treatment is the prevention of fractures tomaintain activities of
daily living and thereby reduce mortality.
Current therapies for OP are based on our understanding of
bone biology. Receptor activator of nuclear factor-kB ligand
(RANKL) is a cytokine that is essential for osteoclast differ-
entiation, activation, and survival. Denosumab, a fully human
monoclonal antibody against RANKL, has been shown to
selectively inhibit osteoclastogenesis. Consequently, the drug
strongly abrogates bone resorption, increases bone mineral
density (BMD), and prevents fragility fractures [1, 2]. The
very recent FREEDOM open-label extension study also dem-
onstrated that nonvertebral fracture rate was decreased for up
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to 7 years after denosumab treatment and that BMD values
increased linearly [3]. Thus, denosumab is considered as one
of the best therapeutic options for osteoporotic patients with
respect to increased BMD, improvement in bone turnover
markers, and prevention of fractures.
Bisphosphonates (BPs) are the most common drugs for
osteoporotic treatment. With their bone anti-resorptive prop-
erties, BPs improve bone turnover, and consequently, increase
BMD and prevent fractures [4]. Nitrogen-containing BPs in-
hibit farnesyl pyrophosphate synthetase in the mevalonate
pathway in osteoclasts [5] to suppress the function of osteo-
clasts and induce their apoptosis, thereby, inhibiting osteoclas-
tic activity. The alendronate (ALN), risedronate (RIS), and
minodronate (MIN) used in the present study are such
nitrogen-containing BPs. BPs and denosumab share the same
mechanism of osteoclastogenesis inhibition.
BPs increase BMD remarkably in postmenopausal patients
with OP, especially over the first few years [6]. However, the
effectiveness of BPs on BMD diminishes over longer treat-
ment periods [7], and so, the continuous use of these drugs in
osteoporotic patients is sometimes limited [8]. In such cases,
alternative drugs, such as denosumab, are required, although
little is known on the improvement bone turnover and/or
BMD by denosumab in primary OP refractory to BP
treatment.
At our institutions, BPs were principally used for osteopo-
rotic patients with low BMD prior to the approval of
denosumab or parathyroid hormone (PTH) in Japan. In our
experience, BMD values increase to various degrees in most
patients in the initial few years of BP treatment and satisfac-
torily increased BMD is frequent. Afterwards, however, some
cases emerge in which BMD values plateau, or even decrease,
in the long term, regardless of the BP used.
The reproducibility and measurement accuracy of BMD
with dual-energy X-ray absorption (DXA) are high using a
scanning table [9]. However, not only hip, but also lumbar,
BMD values vary since obvious measurement errors occa-
sionally occur in daily practice. Therefore, observational
BMD values in each patient do not change in a linear fashion,
and the judgment of treatment effectiveness based on a single
BMD recording is not appropriate; minus measurement errors
of DXA would be likely evaluated as non-responsive cases,
the drugs would be changed, and a minus bias in which BMD
values increase after the treatment alteration would occur. To
address this issue, it is preferable to evaluate the therapy ef-
fectiveness based on multiple value changes over time.
Since its approval in Japan in 2013, we have routinely
prescribed denosumab for cases of poor BP response with
low BMD where increased BMD even decreased after long-
term BP treatment. In this study, we first determined treatment
responsiveness by measurement of lumbar and/or total hip
BMD values at least once every 6 months for 2 years. To
our knowledge, this is the first report on switching from
long-term BP therapy to denosumab in postmenopausal pri-
mary OP refractory to BPs.
Materials and methods
Subjects and measurements
In the period from June 2013 to February 2015, we recruited
118 patients with low lumbar or hip BMD values undergoing
long-term BP treatment, who were only primary OP after
careful differential diagnosis. We defined poor BP responders
as individuals in whom lumbar or hip BMD had not apparent-
ly increased with chronic BP administration. Ultimately, 98
women aged between 54 and 84 years participated in this
study after providing informed consent. These subjects had
received 5 BMD measurements at 6-month intervals during
the 2 years of BP treatment preceding denosumab treatment.
Twenty women had not completed all tests and were dropped
from the study. One man was excluded to avoid gender bias.
ALN, RIS, and MIN were adopted in various regimens as
long-term BP pre-treatment. We did not examine the effects of
individual BP drugs since they were routinely changed for pa-
tients exhibiting low responsiveness. In the patients treated with
BPs, vitamin D and Ca supplementation were not used in all of
the cases. On the other hand, 400 IU vitamin D and 610 mg Ca
supplementation were used in all of the patients treated with
denosumab. All treatments were substituted from BPs to
denosumab at the baseline. Mean (standard deviation [SD]) age
of the 98 subjects was 71.2 (6.9) years and mean (SD) duration
of BP treatment prior to denosumab was 59.9 (34.3) months.
BMDwasmeasured using a DXA fan-beam bone densitom-
eter (Lunar Prodigy; GE Healthcare Bio-Sciences Corp.,
Piscataway, NJ, USA) at the lumbar 1–4 level of the postero-
anterior spine and at the bilateral hips as the mean of the right
and left sides. Fracture sites were avoided for BMD evaluation.
Following the change to denosumab, BMD values were quan-
tified every 4 months for 1 year. Coefficients of variation of the
BMD measurement at lumbar spine and hip were 0.6 and
0.5 %, respectively. Least significant changes of these measure-
ment were accordingly 1.6 and 1.5 %, respectively [9].
At baseline and 4 months of denosumab treatment, we
measured serum bone-specific alkaline phosphatase (BAP)
as a marker for bone formation and urinary N-terminal
telopeptide of type I collagen corrected by creatinine (NTx)
as a bone resorption marker. Serum BAP was evaluated using
a chemiluminescent enzyme immunoassay. Urinary NTx
(Osteomark, Osteox International, Seattle,WA) was measured
using an enzyme-linked immunosorbent assay. After over-
night fasting, serum and first void urine samples were collect-
ed between 8:30 a.m. and 10:00 a.m. Immunoassays were
performed by SRL, Inc. (Tokyo, Japan). Serum concentration
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of corrected calcium (Ca) also was determined by conventional
methods.
Definition of responsive and non-responsive BP groups
If BMD at the baseline minus that at 2 years earlier was neg-
ative, the subject was determined to be a non-responder to BP
treatment. If the total was positive, the subject was defined as a
BP responder. Since 5 BMD readings were obtained over the
2 years prior to denosumab switching, the slopes of linear
regression lines were calculated. A slope of <0 indicated a
non-responder status.
Prior to final group classification, we compared the
groups determined by 2-point data (i.e., baseline and
2 years beforehand) with those determined by the slopes
of linear regression lines using kappa statistics. As
shown in Table 3, 68 as non-responders for the lumber
spine and 30 as responders, while 67 as non-responders
for the hip and 31 as responders. No significant associ-
ations between the groups were observed in this study
for the lumbar spine or hips.
Data analysis
The independent t test was used to investigate for differences
in age, duration of BP use, concentrations of serum corrected
Ca, BAP, and urinary NTx, BMD at 2 years prior to baseline,

















































































































Fig. 1 a Change in BMD at
lumbar spine. In both groups,
lumbar BMD values increased
significantly from before 2 years
to after 1 year of denosumab
treatment (P < 0.001). However,
BMD values in the non-
responsive group did not reach
those in the BP-responsive group
at 1 year of denosumab therapy
(P = 0.080). b Change in BMD at
hips. In the non-responsive group,
BMD values were significantly
decreased (P < 0.001) after
2 years of BP treatment. After
denosmab treatment, hip BMD
values increased in both groups to
a comparable degree (P = 0.709).
As a result, BMD values in the
non-responsive group were lower
than those in the responsive group
at 1 year of denosumab treatment
(P = 0.065).
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baseline, BMD after 1 year of denosumab treatment, and
change in BMD from baseline to 1 year of denosumab be-
tween responders and non-responders at the lumbar spine and
hips.
Comparisons between measurement points (2 years ago,
baseline, and 1 year later) were done using repeated
ANOVAwith Bonferroni correction.
Simple correlation coefficients were calculated for BMD
changes of the lumbar spine and hips for the 2 years of BP pre-
treatment and 1 year of denosumab therapy. Multiple linear
regression analysis with the stepwise method adjusted for age,
duration of BP treatment, and concentrations of serum
corrected Ca, BAP, and urinary NTx was used to evaluate
for associations for the same periods. All data were analyzed
using the Statistical Package for the Social Sciences (SPSS,
version 19.0; IBM Inc., Chicago, IL, USA). P values of less
than 0.05 were considered statistically significant.
This investigation was performed in accordance with the
ethical tenets set forth in the revised 2014 Declaration of
Helsinki. The study was approved by the Institutional Ethics
Committee at Showa Inan General Hospital, and informed
written consent was obtained from all patients.
Results
The overall characteristics of the study subjects are summa-
rized in Table 1 and overall results are presented in Fig. 1a, b.
Bone turnover markers became significantly decreased after
denosumab administration; mean (SD) BAP values before the
treatment change were 10.9 (3.7) μg/L, while those at
4 months of denosumab were 7.8 (2.5) μg/L (P < 0.001).
Mean (SD) urinary NTX values just before denosumab were
24.9 (10.2) nmol BCE/mmol Cr, and those at 4 months were
13.2 (6.8) nmol BCE/mmol Cr (P < 0.001).
At the lumbar spine, there were no significant differences
in age, duration of BP use, serum Ca, serum BAP, urinary
NTx, or BMD at baseline between the groups (Table 2). In
the responsive group, BMD values were significantly in-
creased (P < 0.001) after 2 years of BP treatment, which were
significantly decreased (P < 0.001) in the non-responsive
group. At this point, a significant difference was observed
for lumbar BMD at the baseline (P = 0.021) between the test
groups. After denosumab administration, BMD values in-
creased in both groups. There was no significant difference
in the increase of lumbar BMD values (P = 0.147), although
the augmentation tended to be greater in the non-responsive
group. As a result, the difference in BMD values between the
groups decreased after a year of denosumab treatment to be-
come comparable (P = 0.080). In both groups, lumbar BMD
values increased significantly over the study period
(P < 0.001). However, BMD readings in the non-responsive
group remained lower compared with responsive group at
1 year of denosumab treatment (Fig. 1a).
At the hips, there were no significant differences in age,
duration of BP use, serum Ca, serum BAP, urinary NTx, or
BMD at 2 years prior to baseline between the groups
(Table 3). Similarly to the lumbar data, in the responsive
group, BMD values were significantly increased, while those
for non-responders were significantly decreased, after 2 years
of BP treatment. However, a significant difference was not
observed for hip BMD at the baseline (P = 0.053). After
denosumab initiation, hip BMD values increased comparably
in both groups (P = 0.709), and thus, the BMD in the non-
responsive group remained lower than that in the responsive
group (P = 0.065; Fig. 1b). In the responsive group, hip BMD
values increased significantly over the study period
(P < 0.001). However, over the study period, hip BMD in
the non-responsive group did not change or significantly
increase.
Simple correlation coefficients were −0.337 for the lumbar
spine and −0.339 for the hips (both P = 0.001) for BMD
changes over the study period (Fig. 2a, b). The less lumbar
and hip BMD values were increased by initial BPs, the more
significantly BMD values were increased by denosumab.
Table 1 Characteristics of 98 study subjects
Mean (SD)
Age (years) 71.2 (6.9)
Duration of BP use (months) 59.9 (34.3)
Serum concentration of corrected calcium (mg/dl) 9.20 (0.40)
Serum BAP (μg/L) 10.9 (3.7)
Urinary NTx (nmol BCE/mmol Cr) 24.9 (10.2)
BMD of the lumbar spine 2 years before baseline
(g/cm2)
0.863 (0.097)
BMD of the lumbar spine at baseline (g/cm2) 0.854 (0.100)
Change of BMD from 2 years before baseline at
the lumbar spine (g/cm2)
−0.009 (0.027)
BMD of the lumbar spine at 1 year of
denosumab treatment (g/cm2)
0.893 (0.105)
Change of BMD from baseline to 1 year later at
the lumbar spine for denosumab treatment
(g/cm2)
0.040 (0.031)
BMD of the hip 2 years before baseline
(g/cm2)
0.726 (0.079)
BMD of the hip at baseline (g/cm2) 0.719 (0.081)
Change of BMD from 2 years before baseline
at the hip at (g/cm2)
−0.007 (0.020)
BMD of the hip 1 year of denosumab
treatment (g/cm2)
0.733 (0.082)
Change of BMD from baseline to 1 year later
at hip for denosumab treatment (g/cm2)
0.015 (0.015)
BMD bone mineral density, BAP bone specific alkaline phosphatase,NTx
N-terminal telopeptide of type I collagen corrected by creatinine, BP
bisphosphonate
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Multiple linear regression analysis revealed that a de-
crease in BMD from 2 years before baseline to baseline
(t value = −3.502, P = 0.001) was significantly associ-
ated with an increased change in BMD by denosumab
treatment at the lumbar spine (adjusted R square = 0.113). At
the hips, multiple linear regression analysis also showed that a
decrease in BMD from 2 years before baseline to baseline (t
value = −3.526 P = 0.001) was significantly associated with
an increased change in BMD by denosumab therapy (adjusted
R square = 0.115).
Discussion
BPs usually increase BMD in patients with OP, especially
over the first few years, although the effectiveness of BPs
on BMD diminishes over extended periods [7]. At our
institutions, BPs given to osteoporotic patients with low
BMD regularly increase BMD during initial treatment.
However, some cases of plateauing, or even BMD de-
crease, are encountered regardless of the BP. This study
showed that in non-responsive patients, many of whom
Table 2 Differences in some
parameters between responders
and non-responders for BP
pre-treatment at the lumbar spine
Non-responders Responders P value
Number of patients 68 30
Age (years) 70.7 (0.8) 72.3 (1.3) 0.303
Duration of BP use (months) 59.0 (4.1) 62.0 (6.6) 0.694
Serum corrected calcium (mg/dl) 9.22 (0.05) 9.15 (0.06) 0.420
Serum BAP (μg/L) 11.1 (0.5) 10.6 (0.5) 0.610
Urinary NTx (nmol BCE/mmol Cr) 25.4 (1.2) 23.6 (1.9) 0.420
BMD of the lumbar spine 2 years before
baseline (g/cm2)
0.861 (0.011) 0.868 (0.019) 0.736
BMD of the lumbar spine at baseline (g/cm2) 0.838 (0.011) 0.889 (0.019) 0.021
Change of BMD from 2 years before baseline
at the lumbar spine (g/cm2)
−0.022 (0.002) 0.021 (0.003) <0.001
BMD of the lumbar spine at 1 year of
denosumab treatment (g/cm2)
0.881 (0.011) 0.921 (0.022) 0.080
Change of BMD from baseline to 1 year later
at the lumbar spine for denosumab
treatment (g/cm2)
0.042 (0.003) 0.033 (0.006) 0.147
Results were shown as mean (SEM)
BMD bone mineral density, BAP bone specific alkaline phosphatase, NTx N-terminal telopeptide of type I
collagen corrected by creatinine, BP bisphosphonate
Table 3 Differences in some
parameters between responders
and non-responders for BP pre-
treatment at the hip
Non-responders Responders P value
Number of patients 67 31
Age (years) 71.6 (0.9) 71.3 (0.1) 0.369
Duration of BP use (months) 60.2 (4.3) 59.4 (6.0) 0.916
Serum concentration of corrected calcium (mg/dl) 9.20 (0.05) 9.18 (0.06) 0.840
Serum BAP (μg/L) 11.0 (0.5) 10.7 (0.6) 0.731
Urinary NTx (nmol BCE/mmol Cr) 24.3 (1.1) 26.0 (2.3) 0.461
BMD of the hip 2 years before basseline
(g/cm2)
0.724 (0.010) 0.730 (0.011) 0.732
BMD of the hip at baseline (g/cm2) 0.708 (0.010) 0.742 (0.011) 0.053
Change of BMD from 2 years before baseline at
the hip at (g/cm2)
−0.015 (0.002) 0.012 (0.002) < 0.001
BMD of the hip 1 year of denosumab
treatment (g/cm2)
0.723 (0.010) 0.756 (0.011) 0.065
Change of BMD from baseline to 1 year later at
the hip for denosumab treatment (g/cm2)
0.015 (0.002) 0.014 (0.002) 0.709
Results were shown as mean (SEM)
BMD bone mineral density, BAP bone specific alkaline phosphatase, NTx N-terminal telopeptide of type I
collagen corrected by creatinine, BP bisphosphonate
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had been taking BPs for over 5 years, both lumbar and hip
BMD became significantly decreased over time. These
findings confirmed that BP non-responsiveness developed
during long-term BP treatment in patients with OP.
Recent literature on denosumab has shown that the
drug produces greater increases in BMD than do BPs as
well as a persistent, almost linear increase in spine, total
hip, and femoral neck BMD beyond 3 years and up to
8 years [10]. It is believed that denosumab differs from
BPs, for which the rate of BMD improvement diminishes
and for some drugs becomes negative 2–3 years later,
when the process of secondary mineralization flattens
out [10]. However, the mechanism of reduced BMD after
prolonged BPs remains unknown.
In this study on the switch from BPs to denosumab, the
bone turnover markers that had been inhibited by BPs further
decreased significantly by denosumab. According to direct
comparative studies, denosumab increases significantly great-
er BMD values than do BPs [11]. There have been several
reports describing the effects of denosumab after BP treat-
ment. Roux et al. found that even after BP treatment,
denosumab had stronger inhibitory effects on bone resorption
Fig.2 a Simple correlation
coefficient for lumbar spine.
Simple correlation coefficient was
−0.337 for BMD at the lumbar
spine (P = 0.001) for 2 years of
BP treatment and 1 year of
denosumab treatment. The lower
was the effect on BMD by BPs,
the more significant was the effect
of denosumab treatment on BMD
amelioration. b Simple
correlation coefficient for hips.
Simple correlation coefficient was
−0.339 for BMD at the hip
(P = 0.001) for 2 years of BP
treatment and 1 year of
denosumab treatment. The lower
was the effect on BMD by BPs,
the more significant was the effect
of denosumab treatment on BMD
amelioration.
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and stimulatory effects on BMD [12], confirming that
denosumab produced much more pronounced inhibition of
bone resorption.
Denosumab is well recognized as a potent antiresorptive
agent. However, there have been no reports on the effects
of denosumab in BP-unresponsive cases. Our results
showed that a switch to denosumab from BPs significantly
increased BMD values that had even become decreased by
BP therapy, and thus, was effective in non-responsive pa-
tients. Furthermore, this study revealed that a decrease in
BMD from 2 years prior to baseline to baseline using BP
treatment was significantly associated with an enhanced
BMD change by denosumab both at the lumbar spine and
hips. The mechanism of the increase in BMD caused by
denosumab in the non-responsive group, apart from stron-
ger inhibitory effects on bone resorption, is unclear. We
previously compared the values of bone turnover markers
treated by denosumab without BP pre-treatment with those
after long-term BP treatment. In the pre-treated group,
bone resorption markers were significantly inhibited after
only 1 week of denosumab therapy, while bone formation
markers did not change remarkably, even at 4 months. We
speculate that such bone metabolic inhibitory differences
may indicate a BMD increase [13].
There have been several reports on the effects of PTH after
BP treatment [14]. Blumsohn et al. stated that BMD values
increased by PTH in BP-unresponsive cases. However, in our
experience, PTH after BP treatment is a secondary option
since the impact of PTH after BPs is markedly lower in
Japanese patients [15]. In contrast, denosumab produced sig-
nificant BMD improvements after BP therapy, and may there-
fore represent a better treatment than PTH in Japanese BP-
unresponsive cases.
Our findings showed that BMD values decreased substan-
tially in non-responsive cases with time and a switch to
denosumab increased BMD values. Furthermore, this study
revealed that decreased BMD by prolonged BP pre-
treatment was significantly associated with increased BMD
after denosumab administration both in the lumbar spine and
hips. These results suggesting that patients exhibiting dimin-
ished BP therapy response should immediately change to
denosumab.
The main limitations of this study are its retrospective na-
ture and that a long-term observational period will be needed
to clarify whether or not BMD will increase continuously by
denosumab and to what extent fractures will be prevented.
In this study, clinical treatment results were analyzed retro-
spectively. Thus, there were many subjects who received ex-
tremely long-term BP treatment that could be observed for
more than 2 years for BP responsiveness. Moreover, individ-
ual BP treatments varied since the drugs were changed to
denosumab in the case of a poor BP response after denosumab
approval in Japan in 2013. Based on our results, treatment
should be changed as soon as possible if a BMD increase is
not achieved. Further prospective studies will be challenging
as it may be impossible to perform similar studies to ours from
now on from the ethical standpoint.
In summary, BMD values increased by denosumab follow-
ing BP treatment, even in BP-unresponsive osteoporotic
cases. Thus, it might not be appropriate to continue BPs in
such patients, who should urgently be switched to denosumab.
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